Buy-Side Drug Addiction
Executive Summary
In part II of our two-part series of discussions with fund managers, Steve Dalton of First Capital and Arnie Snider of Deerfield Management, discuss how drug companies face a myriad of challenges likely to depress stock prices, but have performed so well in the last few years that it's been difficult to diversify into other health care sectors. Medical devices don't represent much of an alternative, lacking the growth prospects or pricing flexibility of drugs--indeed, the expected collapse of pricing in the stent market is also likely to have broader repercussions on medical devices in general. Meanwhile, the illiquidity and consequent penalties for investing in small cap stocks has kept investors, despite their general concerns, investing in large cap companies.
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.